Neuland Laboratories Limited Cash Flow Conversion Efficiency
Neuland Laboratories Limited cash flow conversion efficiency. Based on the latest financial reports, Neuland Laboratories Limited (NEULANDLAB) has a cash flow conversion efficiency ratio of -0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-367.47 Million ≈ $-3.97 Million USD) by net assets (Rs16.20 Billion ≈ $175.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Neuland Laboratories Limited (2006–2026)
Cash flow conversion efficiency of Neuland Laboratories Limited from 2006 to 2026. This chart illustrates how Neuland Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NEULANDLAB stock price and chart for real-time trading data and today's change.
Neuland Laboratories Limited Cash Flow Conversion Ratio Explained
Neuland Laboratories Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Neuland Laboratories Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuland Laboratories Limited ranked by their cash flow conversion efficiency. Also see how much is Neuland Laboratories Limited worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Remitly Global Inc
NASDAQ:RELY
|
0.002x |
|
Mandatum Oyj
HE:MANTA
|
0.143x |
|
Boralex Inc
TO:BLX
|
0.019x |
|
Rede Energia Participações S.A
SA:REDE3
|
0.052x |
|
Hesai Group Sponsored ADR
NASDAQ:HSAI
|
-0.004x |
|
Bufab Holding AB
ST:BUFAB
|
0.064x |
|
Tianneng Battery Group Co Ltd
SHG:688819
|
0.063x |
|
AUB Group Ltd
AU:AUB
|
0.040x |
Annual Cash Flow Conversion Efficiency for Neuland Laboratories Limited (2006–2026)
The table below shows the annual cash flow conversion efficiency of Neuland Laboratories Limited from 2006 to 2026. Review Neuland Laboratories Limited free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs18.74 Billion ≈ $202.72 Million |
Rs3.38 Billion ≈ $36.58 Million |
0.180x | -13.31% |
| 2025-03-31 | Rs15.25 Billion ≈ $164.90 Million |
Rs3.17 Billion ≈ $34.32 Million |
0.208x | +4.42% |
| 2024-03-31 | Rs12.83 Billion ≈ $138.72 Million |
Rs2.56 Billion ≈ $27.65 Million |
0.199x | -16.93% |
| 2023-03-31 | Rs9.94 Billion ≈ $107.51 Million |
Rs2.39 Billion ≈ $25.80 Million |
0.240x | +244.27% |
| 2022-03-31 | Rs8.41 Billion ≈ $90.90 Million |
Rs585.81 Million ≈ $6.34 Million |
0.070x | -71.05% |
| 2021-03-31 | Rs7.86 Billion ≈ $85.05 Million |
Rs1.89 Billion ≈ $20.48 Million |
0.241x | +198.11% |
| 2020-03-31 | Rs7.10 Billion ≈ $76.78 Million |
Rs573.41 Million ≈ $6.20 Million |
0.081x | -19.21% |
| 2019-03-31 | Rs6.99 Billion ≈ $75.63 Million |
Rs699.07 Million ≈ $7.56 Million |
0.100x | +395.08% |
| 2018-03-31 | Rs5.58 Billion ≈ $60.35 Million |
Rs112.68 Million ≈ $1.22 Million |
0.020x | -71.52% |
| 2017-03-31 | Rs5.46 Billion ≈ $59.01 Million |
Rs386.81 Million ≈ $4.18 Million |
0.071x | -70.48% |
| 2016-03-31 | Rs1.87 Billion ≈ $20.18 Million |
Rs448.26 Million ≈ $4.85 Million |
0.240x | +194.71% |
| 2015-03-31 | Rs1.62 Billion ≈ $17.48 Million |
Rs131.72 Million ≈ $1.42 Million |
0.081x | -77.18% |
| 2014-03-31 | Rs1.24 Billion ≈ $13.44 Million |
Rs443.82 Million ≈ $4.80 Million |
0.357x | +39.32% |
| 2013-03-31 | Rs1.00 Billion ≈ $10.83 Million |
Rs256.77 Million ≈ $2.78 Million |
0.256x | -60.26% |
| 2012-03-31 | Rs764.81 Million ≈ $8.27 Million |
Rs493.39 Million ≈ $5.34 Million |
0.645x | +39.53% |
| 2011-03-31 | Rs739.68 Million ≈ $8.00 Million |
Rs341.98 Million ≈ $3.70 Million |
0.462x | +109.13% |
| 2010-03-31 | Rs688.95 Million ≈ $7.45 Million |
Rs152.31 Million ≈ $1.65 Million |
0.221x | -22.15% |
| 2009-03-31 | Rs758.08 Million ≈ $8.20 Million |
Rs215.28 Million ≈ $2.33 Million |
0.284x | +186.68% |
| 2008-03-31 | Rs686.76 Million ≈ $7.43 Million |
Rs68.03 Million ≈ $735.72K |
0.099x | +218.14% |
| 2007-03-31 | Rs596.77 Million ≈ $6.45 Million |
Rs-50.04 Million ≈ $-541.16K |
-0.084x | -151.12% |
| 2006-03-31 | Rs523.07 Million ≈ $5.66 Million |
Rs85.81 Million ≈ $927.97K |
0.164x | -- |
About Neuland Laboratories Limited
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.